Market Cap 2.48B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 6,308,000
Avg Vol 8,705,696
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 81%
Beta 1.14
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
ShelleyWarrick
ShelleyWarrick Jul. 7 at 3:59 AM
$VMHG Victory Marine Holdings' Subsidiary Dunn & Groux Beverage Holdings Activates Distribution Across Six U.S. Markets https://finance.yahoo.com/small-business/articles/victory-marine-holdings-subsidiary-dunn-201500164.html $ROOT $NCLH $ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:25 AM
$ABCL A stacked board doesn’t change NK3R biology. Phase 2 still has to hit its endpoint. This is a setup signal, not a data signal. But $JAZZ deal + Sandor + Seely in 3 weeks? Cleanest pre-catalyst setup I’ve seen from $ABCL . Long. NFA.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:24 AM
$ABCL The board sequence tells the story: Nov ’25 → Quake (platform science) Jun 5 → Sandor (Phase 3 execution) Jul 6 → Seely (FDA approval + commercialization) Science ✅ Clinical ✅ Commercial ✅ $ABCL is building the board for a positive readout. Q3 2026 is the test.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:23 AM
$ABCL • Medivation CMO → approved Xtandi → $14B Pfizer buyout • Myovant CEO → approved Myfembree + Orgovyx • Blueprint board → $9.1B Sanofi acquisition • Trained endocrinologist (UCSD) You don’t hire this profile pre-Phase 2 unless you’re planning for after. $ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:23 AM
$ABCL $ABCL just added Dr. Lynn Seely to its board. She’s the ex-CEO of Myovant who took Myfembree (women’s hormonal health) from zero → FDA approval. ABCL635 = NK3R antibody for menopause VMS. Same patient pop. Same FDA division. 8 weeks before Phase 2 data. Not random. 🧵
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 11:41 PM
$ABCL $ABCL is a gamechanger in human longevity through their research in cancer treatments. They are developing world's first non-toxic cancer treatments via antibody/TCE compared to chemotherapy. One of the upsides noted in ABCL635 is the oncology side-benefits. Multibagger stock.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 11:23 PM
$ABCL $ABCL Time passes by… Before long, the market's evaluation and value will change.🚀
0 · Reply
EddieHayes
EddieHayes Jul. 6 at 10:37 PM
A balanced portfolio may not capture every explosive move, but it helps stay positioned across different market cycles. My exposure covers several key themes: $LMND (AI applications) has been the biggest contributor recently, with strong momentum. $OUST has carried performance over the past month. $CRDO and $AAOI continue benefiting from the AI interconnect trend. Healthcare/biotech remains smaller, with $ABCL, LLY, TEM, and HROW staying steady. Metals like SLV, LV, TMQ, and COPX have been weaker, but I’m watching for possible capital rotation. Rare earths remain out of favor, but I still like the long-term case for USAR. The trade-off is simple: less concentration can limit upside, but it also helps manage downside. Over 50% of the portfolio remains in the top positions, keeping strong conviction while maintaining balance. The goal isn’t to own everything. It’s to own quality themes before the market notices.
0 · Reply
PolarBear1
PolarBear1 Jul. 6 at 8:59 PM
$ABCL Crackerjack management, board and medical r&d teams; Phase 2 asset with BB potential; deep pipeline(s); class “A” partnerships globally; 3 years+ cash in the bank
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 6:12 PM
$ABCL Buyers stepping in on every $ABCL dip also respects the long-term resistance and support levels.
0 · Reply
Latest News on ABCL
AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 16 hours ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 16 hours ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 4 weeks ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 7 weeks ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


ShelleyWarrick
ShelleyWarrick Jul. 7 at 3:59 AM
$VMHG Victory Marine Holdings' Subsidiary Dunn & Groux Beverage Holdings Activates Distribution Across Six U.S. Markets https://finance.yahoo.com/small-business/articles/victory-marine-holdings-subsidiary-dunn-201500164.html $ROOT $NCLH $ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:25 AM
$ABCL A stacked board doesn’t change NK3R biology. Phase 2 still has to hit its endpoint. This is a setup signal, not a data signal. But $JAZZ deal + Sandor + Seely in 3 weeks? Cleanest pre-catalyst setup I’ve seen from $ABCL . Long. NFA.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:24 AM
$ABCL The board sequence tells the story: Nov ’25 → Quake (platform science) Jun 5 → Sandor (Phase 3 execution) Jul 6 → Seely (FDA approval + commercialization) Science ✅ Clinical ✅ Commercial ✅ $ABCL is building the board for a positive readout. Q3 2026 is the test.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:23 AM
$ABCL • Medivation CMO → approved Xtandi → $14B Pfizer buyout • Myovant CEO → approved Myfembree + Orgovyx • Blueprint board → $9.1B Sanofi acquisition • Trained endocrinologist (UCSD) You don’t hire this profile pre-Phase 2 unless you’re planning for after. $ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 3:23 AM
$ABCL $ABCL just added Dr. Lynn Seely to its board. She’s the ex-CEO of Myovant who took Myfembree (women’s hormonal health) from zero → FDA approval. ABCL635 = NK3R antibody for menopause VMS. Same patient pop. Same FDA division. 8 weeks before Phase 2 data. Not random. 🧵
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 11:41 PM
$ABCL $ABCL is a gamechanger in human longevity through their research in cancer treatments. They are developing world's first non-toxic cancer treatments via antibody/TCE compared to chemotherapy. One of the upsides noted in ABCL635 is the oncology side-benefits. Multibagger stock.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 11:23 PM
$ABCL $ABCL Time passes by… Before long, the market's evaluation and value will change.🚀
0 · Reply
EddieHayes
EddieHayes Jul. 6 at 10:37 PM
A balanced portfolio may not capture every explosive move, but it helps stay positioned across different market cycles. My exposure covers several key themes: $LMND (AI applications) has been the biggest contributor recently, with strong momentum. $OUST has carried performance over the past month. $CRDO and $AAOI continue benefiting from the AI interconnect trend. Healthcare/biotech remains smaller, with $ABCL, LLY, TEM, and HROW staying steady. Metals like SLV, LV, TMQ, and COPX have been weaker, but I’m watching for possible capital rotation. Rare earths remain out of favor, but I still like the long-term case for USAR. The trade-off is simple: less concentration can limit upside, but it also helps manage downside. Over 50% of the portfolio remains in the top positions, keeping strong conviction while maintaining balance. The goal isn’t to own everything. It’s to own quality themes before the market notices.
0 · Reply
PolarBear1
PolarBear1 Jul. 6 at 8:59 PM
$ABCL Crackerjack management, board and medical r&d teams; Phase 2 asset with BB potential; deep pipeline(s); class “A” partnerships globally; 3 years+ cash in the bank
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 6:12 PM
$ABCL Buyers stepping in on every $ABCL dip also respects the long-term resistance and support levels.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 5:08 PM
$ABCL $10 looks good from here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 3:55 PM
$ABCL It his $7.45 this morning and knocking on door at $8 again, this stock has been incredibly resilient as of late, absolutely loving it!
1 · Reply
KryptonResearch
KryptonResearch Jul. 6 at 3:54 PM
AI-enabled healthcare/research is the most obvious massive winner… $ABCL $SLS $RXRX $IBRX $TEM etc… We take a look at a lesser known name in this space, with similar, if not greater upside potential given their ownership of the data layer. This is the next big sector, we have our pick, but there are so many names that will pay well. https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SmartCapitall
SmartCapitall Jul. 6 at 3:14 PM
$ABCL price action looks too strong for the market to be bracing for a miss. When price keeps grinding like this, traders are clearly leaning toward a solid Phase 2 readout. Not a guarantee, but the tape is telling you uncertainty isn’t getting much weight here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 2:26 PM
$ABCL Algos dumping to pump into tech today, I expect this to only be very short term, use these dips to add to your share count! Cheers!
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:22 PM
$ABCL $ABCL AbCellera Appoints Dr. Lynn Seely to its Board of Directors: “AbCellera is well positioned for growth as it moves multiple product candidates, developed by its exceptional research team and designed to bring meaningtul new treatments to patients, into early- and late-stage clinical development.", said Dr Seely
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:20 PM
$ABCL Most failed biotech reversals share the same pattern: weak volume + early breakout + immediate rejection $ABCL is attempting the opposite setup: strong volume + base retest + upward expansion
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 2:00 PM
$ABCL As usual sick trading personality as the stock drops clowns here get too excited they dont actually post but in drops they come out like maggots and start cheerleading Especialy DEMAMP and other few of his papers traders
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 1:53 PM
$ABCL Adding and loading buying oppurtunity selling my shirt to buy ABCL Typical Paid pumpers or papers traders patter, This POS has not delviered returns for investors for last 5-6 years. Until this reaches $15 this POS is much over hyped and under performing junk -
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 1:53 PM
0 · Reply
Rastafari
Rastafari Jul. 6 at 1:48 PM
$ABCL Buying opportunity people!back the truck up. We will see $8 by COB!
0 · Reply
sogenerous
sogenerous Jul. 6 at 1:47 PM
$ABCL again by the time everyone sees its a "nice" chart with big green bars - sub 100 IQs - its too late often in the short -term and retracement looming
0 · Reply